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Abstract
Among patients with proteinuric chronic kidney disease (CKD), current guideline 
recommendations mandate the use of agents blocking the renin-angiotensin-aldosterone-system 
(RAAS) as first-line antihypertensive therapy on the basis of randomized trials demonstrating that 
RAAS-inhibitors are superior to other antihypertensive drug classes in showing nephropathy 
progression to end-stage-renal-disease. However, the opportunities to adequate RAAS-blockade in 
CKD are often limited and an important impediment is the risk for hyperkalemia, especially when 
RAAS-inhibitors are used in maximal doses or are combined. Accordingly, a large proportion of 
patients with proteinuric CKD may not have the anticipated renoprotective benefits, since RAAS-
blockers are often discontinued due to incident hyperkalemia or administered at suboptimal doses 
for fear of developing hyperkalemia. Two newer potassium-binders, patiromer and sodium 
zirconium cyclosilicate (ZS-9), have been shown to effectively and safely reduce serum potassium 
levels and maintain long-term normokalemia in CKD patients receiving background therapy with 
RAAS-inhibitors. Whether these novel potassium-lowering therapies can overcome the barrier of 
hyperkalemia and enhance the tolerability of RAAS-inhibitor use in proteinuric CKD awaits 
randomized trials.
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INTRODUCTION
Among patients with proteinuric chronic kidney disease (CKD), guidelines mandate the use 
of agents blocking the renin-angiotensin-aldosterone-system (RAAS) based on randomized 
clinical trials (RCTs) demonstrating that these agents are superior to other antihypertensive 
drug classes in retarding the progression of kidney failure to end-stage-renal-disease 
(ESRD).1–5 Unlike the strong guideline recommendations, the opportunities to provide 
adequate RAAS-blockade are often limited, due to the risk of inducing hyperkalemia, for 
example in patients with increased risk, such as those with an estimated-glomerular-
filtration-rate (eGFR) <45 ml/min/1.73m2, diabetes or heart failure.6,7
In addition to the above, the premature termination of some RCTs evaluating the potential 
renal benefits of dual RAAS-blockade due to excess risk of hyperkalemia and acute kidney 
injury (AKI)8, 9 indicates that in the absence of a more effective treatment of hyperkalemia, 
the use of RAAS-blockade towards renoprotection in proteinuric CKD may have reached its 
limit. A 2015 network meta-analysis revives the concept of combined RAAS-blockade as an 
effective approach to prevent ESRD among patients with diabetic nephropathy.10 Recent 
advances in the management of hyperkalemia with the 2015 Food and Drug Administration 
(FDA) approval of patiromer and the development of sodium zirconium cyclosilicate 
(ZS-9)11,12 that awaits approval offer hope that these novel potassium-binders may reduce 
the high discontinuation rates of RAAS-blockers and possibly enable their use at higher 
doses or in combination therapy.
In this article, we provide an overview of the risk of hyperkalemia with the use RAAS-
blockers in CKD patients. We also discuss recent RCTs evaluating the efficacy and safety of 
new potassium-binders in hyperkalemic patients treated with RAAS-blockers and we 
conclude with an overview of ongoing trials and directions for future research.
OVERVIEW OF HYPERKALEMIA IN CKD PATIENTS TREATED WITH RAAS-
BLOCKERS
Among patients with uncomplicated hypertension treated with RAAS-inhibitor 
monotherapy, the incidence of hyperkalemia is as low as 2%.7 Risk factors for hyperkalemia 
in CKD are as follows: eGFR <45 ml/min/1.73m2, baseline sK ≥4.5 mEq/L, older age, co-
existence of diabetes or heart failure and RAAS-blockade.6,8,9,12,13
Incidence of hyperkalemia in randomized trials
The clear renoprotective action of angiotensin-converting-enzyme-inhibitors (ACEIs) and/or 
angiotensin-receptor-blockers (ARBs) demonstrated in phase III trials enrolling patients 
with proteinuric nephropathy should be balanced against the associated risk of hyperkalemia 
(Table 1).14–19 In the Irbesartan Diabetic Nephropathy Trial (IDNT),18 1,715 patients with 
type 2 diabetic nephropathy were randomized to irbesartan (300 mg/day), amlodipine (10 
mg/day) or placebo for 2.6 years. The incidence of hyperkalemia (defined as sK ≥6.0 
mEq/L) was 18.6% in irbesartan-treated participants versus 6% in placebo-treated 
participants (P<0.001).18 In the Reduction of Endpoints in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL),15 1,513 patients with overt diabetic nephropathy were 
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randomized to losartan (50–100 mg/day) or placebo, both administered in addition to 
conventional antihypertensive therapy. Losartan increased the risk for hyperkalemia versus 
placebo [Hazard Ratio (HR): 2.0; 95% Confidence Interval (CI): 1.56–2.57].15 In a post-hoc 
analysis,20 the incidence of hyperkalemia (defined as sK ≥5.5 mEq/L) over the first 6 
months was 10.8% in losartan-treated participants versus 5.1% in placebo-treated 
participants. Losartan treatment was independent predictor of incident hyperkalemia at 6 
months [Odds Ratio (OR: 2.80; 95% CI: 2.00–3.90].20
The effect of RAAS-blockade on potassium balance among patients with non-diabetic CKD 
was investigated in the African American Study of Kidney Disease (AASK).19 In this trial, 
1,094 African-Americans with hypertensive nephrosclerosis and macroalbuminuria were 
randomized to achieve goal mean arterial pressure 102–107 mmHg or ≤92 mmHg and to 
initial therapy with metoprolol (2.5–10 mg/day), ramipril (2.5–10 mg/day) or amlodipine 
(5–10 mg/day) in a 3×2 factorial design.19 In a secondary analysis stratified according to the 
baseline level of eGFR, the incidence of hyperkalemia was 11.2% in the stratum of eGFR 
≤40 ml/min/1.73m2 versus only 1.6% in those with baseline eGFR >40 ml/mon/1.73m2.21 
Ramipril treatment was associated with higher risk for hyperkalemia as compared with 
amlodipine (HR: 7.00; 95% CI: 2.29–21.39) and metoprolol (HR: 2.85; 95% CI: 1.50–5.42).
21
Dual RAAS-blockade—Phase III trials revealed that the approach of combining an ACEI 
with an ARB, although potentially beneficial in enhancing the anti-proteinuric effect of 
monotherapy, aggravates the risk of hyperkalemia and AKI (Table 2). In the Ongoing 
Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET),
13
 25,620 patients with high cardiovascular risk profile were randomized to ramipril (10 mg/
day), telmisartan (80 mg/day) or their combination for 56 months. The incidence of 
hyperkalemia (defined as sK ≥5.5 mEq/L) was higher in the combination arm relative to 
monotherapy (1.29 vs 0.74 hyperkalemic events per 100 patients-months of follow-up, 
P<0.001).13 In the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints 
(ALTITUDE),9 8,561 type 2 diabetic patients with CKD, cardiovascular disease or both 
were randomized to aliskiren (300 mg/day) or placebo in addition to standard therapy with 
an ACEI or ARB. This trial was prematurely terminated due to excess risk of hypotension 
(12.1% vs 8.3%, P<0.001) and hyperkalemia (11.2% vs 7.2%, P<0.001) in the combination 
group.9 The Veteran’s Administration Nephron-Diabetes Trial (VA-NEPHRON-D) was also 
prematurely stopped owing to safety concerns.8 In this trial, 1,448 patients with type 2 
diabetic nephropathy already treated with losartan (100 mg/day) were randomized to 
lisinopril (10–40 mg/day) or placebo. Combination therapy was associated with 70% excess 
risk for AKI (HR: 1.70; 95% CI: 1.3–2.2) and 2.8-fold higher risk for hyperkalemia (HR: 
2.8; 95% CI: 1.8–4.3).8 When the VA-NEPHRON-D trial was closed, dual RAAS-blockade 
showed a strong trend to lowering the risk of ESRD versus monotherapy (HR: 0.66; 95% CI: 
0.41–1.07, P=0.07).8 This trend suggests a potential emerging signal for renoprotection with 
combination therapy.22
The notion that the premature termination of the VA-NEPHRON-D should not be 
conclusively considered as the end of dual RAAS-blockade is supported by a 2015 network 
meta-analysis of 157 RCTs incorporating data from 43,256 participants with diabetic kidney 
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disease.10 This meta-analysis showed that dual RAAS-blockade was associated with 38% 
reduced risk for incident ESRD versus placebo (OR: 0.62; 95: CI: 0.43–0.90). Combination 
therapy increased the risks of hyperkalemia (OR: 2.69; 95% CI: 0.97–7.47) and AKI (OR: 
2.69; 95% CI: 0.98–7.38),10 but the 95% CI of the ORs crossed 1.0.
Add-on therapy with mineralocorticoid-receptor-antagonists (MRAs) may be an alternative 
approach to enhance the renoprotective action of monotherapy with ACEIs/ARBs. An earlier 
meta-analysis of 11 RCTs showed that MRA therapy induced an additive reduction in 
proteinuria [Weighted Mean Difference (WMD): −0.8 g/day; 95% CI: −1.27 to −0.33 g/day]. 
This anti-proteinuric effect was accompanied by a slower eGFR decline over time that was 
not significant (WMD: −0.70 ml/min/1.73m2; 95% CI: −4.73 to 3.34 ml/min/1.73m2). 
However, MRA therapy increased the risk for hyperkalemia (RR: 3.06; 95% CI: 1.26–7.41).
23
 A subsequent meta-analysis of 27 RCTs confirmed that MRA therapy offers an additive 
proteinuria-lowering effect [Standardized Mean Difference (SMD): −0.61; 95% CI: −1.08 to 
−0.13], but raises the risk of hyperkalemia (RR: 2.0; 95% CI: 1.25–3.20).24 Phase III trials 
evaluating the effect of add-on MRA therapy on nephropathy progression are unavailable.
A newly-introduced, selective, non-steroidal MRA named finerenone offers promise for 
similarly effective anti-proteinuric action with established steroidal MRAs, without causing 
a significant sK elevation.25 The efficacy of finerenone was tested in the Mineralocorticoid 
Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) trial,26 in which 
821 diabetic patients with high or very high albuminuria already treated with ACEIs/ARBs 
were randomized to finerenone (1.25–20 mg/day) or placebo. Finerenone improved 
albuminuria in a dose-dependent manner; the UACR was reduced by 33% and 38% versus 
baseline in the groups of 15 and 20 mg/day, whereas the incidence of hyperkalemia was as 
low as 4.1% and 2.6%, respectively.26 However, the slight sK elevation in response to 
finerenone therapy could, at least partially, be explained by the lower risk of ARTS-DN 
participants for developing hyperkalemia. Above 60% of study participants had an eGFR 
>60 ml/min/1.73m2 at baseline, whereas patients with sK >4.8 mEq/L at screening visit and 
those with eGFR <45 ml/min/1.73m2 under treatment with a potassium-sparing were 
excluded.26 Phase III trials with finerenone to demonstrate cardio-renal protection with 
lower hyperkalemia risk in those with diabetic nephropathy are ongoing and will better 
clarify the risk for hyperkalemia in relationship to the perceived benefits for the heart and 
kidney.25
Incidence of hyperkalemia in observational studies
The association of RAAS-blockade with hyperkalemia development was explored in a 
number of observational studies summarized in Table 3. In a cohort of 1,818 outpatients 
initiating ACEI therapy in a Veterans Affairs Medical Center in USA during 1992–1993, the 
incidence of hyperkalemia was 11%.27 Over a 1-yearlong follow-up, the re-occurrence of 
severe hyperkalemia (defined as sK >6 mEq/L) in patients remaining on an ACEI was 10%.
27
 In a subsequent retrospective analysis of CKD patients starting an ACEI-based therapy 
during 1998–2006, 2.8% out of 5,171 participants developed hyperkalemia; older age, 
history of diabetes or heart failure, the use of potassium-sparing diuretics and a high ACEI 
dose were independent predictors of hyperkalemia.28 In a small interventional study of 46 
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patients with stage 3–4 CKD and resistant hypertension, add-on MRA therapy was 
associated with a mean sK elevation of 0.4 mEq/L, with 17.3% of patients manifesting 
hyperkalemia during follow-up.29
To investigate the incidence of hyperkalemia, Einhorn et al.30 performed a retrospective 
analysis of electronic records of 245,808 patients cared for over a single year in the Veterans 
Health Administration in USA. The overall incidence of hyperkalemia during 2005 was 
3.2%. RAAS-inhibitor use was associated with 41% increased risk of hyperkalemia (OR: 
1.41; 95% CI: 1.37–1.44).30 After multivariate adjustment, the incidence of hyperkalemia 
among patients treated with RAAS-blockers was higher in those with compared to those 
without CKD (Incidence rate: 7.67 vs 2.30 events per 100 patients-months of follow-up).30
Mortality hazard associated with hyperkalemia in CKD patients
Observational cohort studies suggest a U-shaped association between sK levels and 
mortality in CKD patients (Table 4).31–33 In a prospective analysis of 820 patients 
participating in the Renal Research Institute CKD (RRI-CKD) study,31 compared with 
normokalemic patients (i.e., sK 4.0–5.5 mmol/L), those with a time-varying sK ≤4 mmol/L 
(HR: 1.73; 95% CI: 1.02–2.95) as well as those with sK >5.5 mmol/L (HR: 1.57; 95% CI: 
0.78–3.20) had increased mortality risk over 2.6 years of follow-up.31
A subsequent analysis of 36,359 CKD patients enrolled in an electronic medical record 
registry during 2005–2009, compared with the reference category of sK 4.0–4.9 mmol/L, a 
time-varying sK <3.5 mmol/L (HR: 1.95; 95% CI: 1.74–2.18) and a sK >5.5 mmol/L (HR: 
1.65; 95% CI: 1.48–1.84) were both associated with excess mortality over a mean follow-up 
of 2.6 years.33 In another retrospective analysis of 56,266 patients with stage 3–4 CKD 
enrolled in an electronic registry of HeathCare Partners in California during 2009–2013,32 
hypokalemia defined as sK <3.5 mEq/L [Incidence Rate Ratio (IRR): 3.05; 95% CI: 2.53–
3.68] and hyperkalemia defined as sK >6 mEq/L were both associated with increased 
mortality (IRR: 3.31; 95% CI: 2.52–4.34).32
The association of sK levels with mortality was explored in a cohort of 2,662,462 US 
veterans participating in the Racial and Cardiovascular Risk Anomalies in Chronic Kidney 
Disease (RCAV) Study.34 Using the sK level 4.2 mmol/l as reference standard, both higher 
and lower sK was associated with higher mortality hazard. This U-shaped pattern was fairly 
similar in African-Americans and non African-Americans, suggesting that race did not 
modify the risk relationship of sK with mortality.34
Non-mortal associations of hyperkalemia
Apart from the direct association of hyperkalemia with mortality, hyperkalemia may be 
associated with physician reluctance to provide adequate RAAS-blockade. In a recent 
analysis of 194,456 outpatients enrolled in the Geisinger Health System, hyperkalemia 
(defined as sK >5.5 mEq/L) occurred in 2.3% of study participants over a 3-year-long 
follow-up.35 The occurrence of a hyperkalemic event resulted in alterations in the 
antihypertensive regimen in 26.4% of cases. The most commonly recorded medication 
change was discontinuation and/or dose reduction of RAAS-inhibitors or potassium-sparing 
diuretics (29.1% and 49.6% of people receiving these medications, respectively).35 In the 
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aforementioned electronic registry of HeathCare Partners in California, the occurrence of 
hyperkalemia was associated with a higher likelihood of discontinuing RAAS-blockers 
regardless of the eGFR level (IRR: 1.70, 2.21, 1.71 and 1.81 for eGFR strata 50–59, 40–49, 
30–39 and <30 ml/min/1.73m2 respectively, P<0.001 for all strata).32 Whether discontinuing 
RAAS-blockers alters cardiovascular and renal risk in those prone to hyperkalemia is 
unknown.
POTASSIUM-BINDERS FOR LONG-TERM MANAGEMENT OF 
HYPERKALEMIA IN CKD
Sodium polystyrene sulfonate
Sodium polystyrene sulfonate (SPS), a resin that exchanges potassium for sodium in the 
large intestine, was approved by the FDA in 1958 and has become an important part of 
hyperkalemia management,6,11,12 Given that the FDA approval of drugs before 1962 was not 
necessarily evidence-based, it is unsurprising that RCTs to prove the efficacy and safety of 
SPS are absent.36 Earlier uncontrolled interventional studies revealed that the potassium-
lowering effect of SPS is associated with the pretreatment sK levels;37 this observation 
suggests that the major factor determining the efficacy of SPS is the severity of 
hyperkalemia.
In a 2015 RCT, 33 outpatients with CKD and mild hyperkalemia (sK: 5–5.9 mEq/L) were 
randomly assigned to SPS (30 g orally once daily) or placebo for 7 days.38 SPS was superior 
to placebo in reducing sK (between-group difference: −1.04 mEq/L; 95% CI: −1.37 to 
−0.71, P<0.001), without significant increase in the incidence of hypernatremia and 
gastrointestinal side-effects.38 Owing to the short duration of therapy, this trial cannot 
support the safety of SPS for long-term hyperkalemia management. The current clinical 
experience suggests that the long-term use of SPS is associated with volume overload, 
hypernatremia, diarrhea and gastrointestinal intolerance.6,11,12
Importantly, in 2009, the FDA released a black box warning for SPS on the basis of 
accumulated data showing a high incidence of colonic necrosis attributable to this 
compound.39–41 A 2013 meta-analysis of adverse gastrointestinal adverse effects of SPS 
identified 30 reports encompassing 58 patients.39 Colon was the most frequent site of injury 
in 76% of the cases, transmural necrosis the most common pathology (62%) and the 
gastrointestinal injury was associated with a mortality rate of 33%.39 This potentially life-
threatening complication is a serious safety concern, particularly when SPS is combined 
with sorbitol, but can also occur without sorbitol. The authors of the meta-analysis identified 
as risk factors for gastrointestinal injury with SPS use as kidney disease, transplantation, and 
a post-operative state.39
Newer potassium-blinders
Two newer potassium-binders, patiromer and ZS-9, have been evaluated in phase II and III 
RCTs, showing excellent potassium-lowering efficacy, highly predicable dose-response 
relationship and favorable side-effect profile.6,11,12 Patiromer is an FDA-approved, organic, 
non-absorbed, sodium-free, potassium-binding polymer that exchanges potassium for 
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calcium in the gastrointestinal track (Figure 1).42–44 ZS-9 is a non-absorbed, insoluble, 
inorganic crystal, which selectively entraps potassium in the gastrointestinal tract in 
exchange for sodium and hydrogen (Figure 2).42,43,45 Similarities and differences between 
older and newer potassium-binders in their pharmacological characteristics and side-effect 
profile are provided in Table 5. The results of phase II and III RCTs evaluating efficacy and 
safety of patiromer and ZS-9 is summarized in Table 6 and discussed further below.
Studies with Patiromer—In the Evaluation of RLY5016 in Heart Failure Patients 
(PEARL-HF) trial,46 105 patients with heart failure and a history of hyperkalemia resulting 
in discontinuation of RAAS-inhibitors and/or β-blockers within the 6 previous months or 
CKD were randomized to double-blind patiromer (30 g/day) or placebo for 4 weeks. Study 
participants were also administered spironolactone, initiated at 25 mg/day, a dose that was 
up-titrated to 50 mg/day at Day 15, if sK was <5.1 mEq/L. Compared with placebo, 
patiromer significantly lowered sK levels during follow-up, with a between-group difference 
of −0.45 mEq/L (P<0.001); the incidence of hyperkalemia was lower (7.3% vs 24.5%, 
P=0.015) and the proportion of patients on spironolactone 50 mg/day was higher (91% vs 
74%, P=0.019) in patiromer-treated participants.46 Side effects were mainly gastrointestinal 
(patiromer group 21% vs placebo group 6%). The rate of drug discontinuation was identical 
in both study arms (7% vs 6%).46 The most important finding of the PEARL-HF trial was 
that patiromer enabled the administration of spironolactone in a larger proportion of patients 
having the indication of MRA therapy, despite their propensity for hyperkalemia.
In the two-part, single-blind, phase 3 study evaluating the efficacy and safety of patiromer 
for the treatment of hyperkalemia (OPAL-HK) trial,47 243 hyperkalemic patients with stage 
3–4 CKD already treated with RAAS-blockers entered an initial 4-week, single-blind 
treatment phase, during which patiromer was administered at an initial dose of 4.2 g or 8.4 g 
twice daily. Participants with baseline sK 5.5–6.5 mmol/L, in whom sK was lowered at a 
level ranging from 3.8 to 5.1 mmol/l at the end of this phase, entered a subsequent 8-week, 
randomized, placebo-controlled withdrawal phase. In this part of the trial, patients were 
randomized to continue patiromer at the same dose as their week 4 dose in the initial phase 
or switched over to placebo.47 In the initial phase, a significant reduction of 1.01±0.03 
mmol/l in sK was noted. In the randomized withdrawal phase, a significant elevation of 0.72 
mmol/l in sK was noted with placebo, whereas sK remained unchanged in those randomized 
to continue patiromer. The proportion of patients with recurrent hyperkalemia during the 
withdrawal phase was 4-fold higher with placebo than with patiromer (60% vs 15%, 
P<0.001). The most commonly reported adverse event was mild-to-moderate constipation.47
Treatment of hyperkalemia in patients with hypertension and diabetic nephropathy 
(AMETHYST-DN) was a phase II, multi-centre, open-label, randomized, dose-ranging trial 
aiming to evaluate the long-term potassium-lowering efficacy and safety of patiromer in 
hyperkalemic patients with diabetic nephropathy already treated with RAAS-blockers.48 
Study participants were classified into mild or moderate hyperkalemia strata according to the 
level of baseline sK and were randomized to different starting doses of patiromer (mild 
stratum: 4.2, 8.4 or 12.6 g twice daily; moderate stratum: 8.4, 12.6 or 16.8 g twice daily). 
Study investigators were allowed to up-titrate these doses aiming to maintain sK <5 mEq/L 
during follow-up.48 Between the baseline and week 4, significant reductions of −0.47±0.04 
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mEq/L and −0.92±0.08 mEq/L in sK were noted in both mild and moderate hyperkalemia 
strata. During the maintenance phase (Week 4 – Week 52), significant reductions in sK 
levels were evident at each monthly follow-up visit in patients with mild and moderate 
hyperkalemia. Hypomagnesaemia (defined as serum magnesium <1.8 mg/dl), which was the 
most commonly reported adverse event, occurred in 7.2% of participants; hypokalemia 
(defined as sK <3.5 mEq/L) occurred in 5.6% of patients.48 These electrolyte disturbances 
were not associated with higher incidence of cardiac arrhythmias during follow-up.
Studies with ZS-9—In a multi-centre, double-blind, phase III trial, 753 hyperkalemic 
patients with heart failure, CKD or diabetes were randomized to ZS-9 (at a dose of 1.25g, 
2.5g, 5g or 10g) or placebo 3 times a day for 48 hours.49 Patients reaching normokalemia at 
48 hours had randomized withdrawal of the drug: ZS-9 or placebo once daily. The aim of 
this study was to investigate the efficacy of ZS-9 in maintaining normokalemia until Day 15. 
Significant dose-dependent reductions in sK levels were noted between the baseline and the 
evaluation at 48 hours (0.46 mmol/L in the 2.5g group, 0.54 mmol/L in the 5g group and 
0.73 mmol/L in the 10g group, relative to a mean reduction of 0.25 mmol/L with placebo, 
P<0.001 for all comparisons).49 In the randomized withdrawal phase, ZS-9 was superior to 
placebo in maintaining normokalemia at Days 3 and 15; episodes of recurrent hyperkalemia 
were observed in patients assigned to placebo who had been treated with ZS-9 at doses of 5g 
and 10g during the initial phase of the trial.49 The incidence of adverse events was not 
different between the active-treatment and placebo groups (initial phase: 12.9% vs 10.8%; 
maintenance phase: 25.1% vs 24.5%, respectively), with diarrhea being the most commonly 
reported complication.49
In The Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance 
(HARMONIZE) study,50 258 hyperkalemic patients with CKD, heart failure or diabetes 
received ZS-9 at a dose of 10g 3 times daily for 48 hours in an initial open-label, non-
randomized phase. Subsequently, those patients achieving normokalemia were randomized 
to double-blind ZS-9 (at doses of 5g, 10g, or 15g once daily) or placebo for 28 days. In the 
initial open-label phase, a mean reduction of −1.1 mEq/L (95% CI: −1.1 to −1.0 mEq/L, 
P<0.001) in sK was noted from baseline to 48 hours; the proportion of patients achieving 
normokalemia at 48 hours was 98%. In the randomized phase, ZS-9 reduced sK during days 
8–29 in a dose-dependent manner (differences relative to placebo: −0.3, −0.6 and −0.7 
mEq/L for 5g, 10g and 15g doses of ZS-9, respectively, P<0.001 for all comparisons). The 
proportion of patients maintaining normokalemia was significantly higher in the active-
treatment groups versus placebo.50 Therapy with ZS-9 was well-tolerated and the incidence 
of adverse events was comparable between the active-treatment and placebo groups. ZS-9 
increased the incidence of edema in a dose-dependent manner (2%, 6%, and 14% for 5g, 
10g, and 15g ZS-9 doses vs 2% with placebo), but edema occurrence had no impact on the 
drug tolerability.50 Since ZS-9 contains sodium, the release and absorption of sodium in the 
intestine is the most likely mechanistic explanation for the dose-dependent edema 
occurrence. The clinical importance of ZS-9-inducible sodium retention, particularly in 
susceptible patients with heart failure or CKD, remains to be elucidated in ongoing trials.
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PERSPECTIVES
Currently available RCTs have demonstrated that newer potassium-lowering therapies can 
effectively and safely correct hyperkalemia and maintain normokalemia in patients receiving 
background treatment with RAAS-blockers.46–51 It has to be noted, however, that the long-
term (i.e., >12 months) efficacy and safety of newer potassium-binders remains to be 
ascertained. Even with increased numbers in modern day RCTs of potassium binders, the 
power to identify with confidence rare events such as colonic necrosis is limited. Thus, real-
world experience will be needed to establish the longer term safety of the newer agents. The 
low cost and the accumulated clinical experience with SPS should compel us to conduct 
additional RCTs to determine the role of SPS in the long-term management of hyperkalemia 
and explore its comparative effectiveness and safety with newer potassium-binders.
The next step is to evaluate whether newer potassium-binders may overcome the barrier of 
hyperkalemia and enable the administration of ACEIs/ARBs at higher doses or in 
combination in patients with anticipated benefits from such a therapeutic approach (i.e., 
patients with proteinuric nephropathy, patients with heart failure and reduced left ventricular 
ejection fraction). A step in this direction is the trial of spironolactone with.52,53 This 
ongoing phase II trial is planning to recruit 290 CKD patients with resistant hypertension 
and sK 4.3–5.1 mEq/L. Eligible patients will be randomized to spironolactone plus blinded 
patiromer or spironolactone plus blinded placebo and the primary endpoint is the between-
group difference in the proportion of patients remaining on spironolactone after 12 weeks of 
therapy.52 The use of new potassium-binders towards cardiovascular and renal risk reduction 
with combined RAAS-blockade therapy will require phase III trials.
Another important area of investigation is the efficacy and safety of new potassium-binders 
in hemodialysis patients. This patient population is highly susceptible to hyperkalemia, 
particularly during the long interdialytic nterval.54 A small study showed that treatment with 
patiromer over 7 days reduced sK levels and enhanced fecal potassium excretion as 
compared with the pre-treatment 7-day period in 6 hyperkalemic hemodialysis patients;55 
these promising results enable the design of phase II trials aiming to evaluate the 
maintenance of normokalemia over a longer period.56
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Figure 1. Chemical structure of patiromer and the calcium-sorbitol counter ion
Image reproduced with permission from Relypsa, Inc., VELTASSA® Prescribing 
Information 2016. Redwood City, CA
Georgianos and Agarwal Page 13
Kidney Int. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Structure of Sodium zirconium cyclosilicate
Pore detail with potassium ion (A), sodium ion (B), and calcium ion (C). Blue sphere 
indicates oxygen atoms; green spheres, silicon atoms; and red spheres, zirconium atoms. 
Reprinted from Stavros et al.45 with permission of the publisher. Copyright: © 2014 Stavros 
et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited.
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Table 5
Similarities and differences among sodium polystyrene sulfonate, patiromer and sodium zirconium 
cycosilicate in pharmacological characteristics and side-effect profile.
Characteristic SPS Patiromer ZS-9
FDA approval Yes (1958) Yes (2015) Pending
Chemical structure
Non-absorbed, organic, sodium-
containing resin
Non-absorbed, organic, sodium-free 
polymer
Non-absorbed, insoluble, 
inorganic, sodium-containing 
crystalline silicate
Mechanism of action
Nonspecific cation binding in 
exchange for sodium
Nonspecific cation binding in 
exchange for calcium
Selective potassium binding in 
exchange for sodium and 
hydrogen
Administration Oral or rectal Oral Oral
Formulation
Suspension in sorbitol or 
dissolvable powder Oral suspension Oral suspension
Location of action Colon Distal colon predominantly Entire intestinal track
Onset of action 1–2 hours 7 hours 1 hour
Dosing
•15–60 g/day orally
• 30–50 g/day rectally 8.4 – 25.2 g daily
5–10 g daily, depending on 
FDA recommendations
Drug interactions
•Cation donating agents may 
interfere with the potassium-
lowering efficacy of SPS.
• Intestinal obstruction when 
aluminum hydroxide was combined 
with SPS.
• Possible decreased absorption of 
co-administered lithium and 
thyroxin.
• Co-administration with non-
absorbable cation-donating antacids 
and laxatives was associated with 
systemic alkalosis.
• Reduced systemic exposure of 
coadministered ciprofloxacin, 
metformin, and levothyroxine.57
• No interaction when patiromer and 
these drugs were taken 3 hours apart.57
• No significant drug-drug 
interactions involving ZS-9 in 
currently available clinical 
studies
Commonly reported 
adverse reactions
•GI disorders (i.e., constipation, 
nausea, vomiting, diarrhea)
• Hypernatremia
• Hypokalemia
• Metabolic alkalosis
• Volume overload
•GI disorders (i.e., constipation, 
nausea, vomiting, diarrhea, flatulence)
• Hypokalemia
• Hypomagnesemia
• GI disorders (i.e., 
constipation, nausea, vomiting, 
diarrhea)
• Hypokalemia
• Edema
Serious adverse events Colonic necrosis None None
Abbreviations: FDA; Food and Drug Administration; GI= gastrointestinal; sK= serum potassium; SPS= sodium polystyrene sulfonate; ZS-9= 
sodium zirconium cycosilicate;
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